Back to top
more

Cigna Group (CI)

(Delayed Data from NYSE)

$315.22 USD

315.22
2,655,167

-3.17 (-1.00%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $315.09 -0.13 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 27% (184 out of 251)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cigna Group (CI) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cigna (CI) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the most recent trading session, Cigna (CI) closed at $343.94, indicating a +0.49% shift from the previous trading day.

Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout

by Zacks Equity Research

The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.

An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook

by Zacks Equity Research

Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.

Here's Why You Should Add Cigna (CI) Stock to Your Portfolio

by Zacks Equity Research

Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.

The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics

by Zacks Equity Research

The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Molina (MOH) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions

by Zacks Equity Research

Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.

Centene (CNC) Up 3.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ensign Group (ENSG) Up 30.8% in 6 Months: More Growth Ahead?

by Zacks Equity Research

Ensign Group's (ENSG) growing strength in its Skilled Services business is a major upside.

Wall Street Bulls Look Optimistic About Cigna (CI): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Cigna (CI) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Derek Lewis headshot

3 Top-Ranked Stocks to Buy for Stability

by Derek Lewis

Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.

HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.

The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers

by Zacks Equity Research

The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.

Rajani Lohia headshot

5 Valuable Low Price-to-Sales Stocks to Refresh Your Portfolio

by Rajani Lohia

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like TAP, PAGS, CI, STT and FHN hold promise.

Centene (CNC), Pyx Health Unite to Treat Mental Health Issues

by Zacks Equity Research

Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.

CI vs. HUM: Which Stock Is the Better Value Option?

by Zacks Equity Research

CI vs. HUM: Which Stock Is the Better Value Option?

If You Invested $1000 in Cigna a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Why Cigna (CI) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Humana (HUM) Collaborates With Veda to Enhance Efficiency

by Zacks Equity Research

Humana (HUM) partners with Veda to enhance the quality of provider directories.

Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cigna (CI) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Cigna Group (CI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Brookdale Senior's (BKD) Q4 Loss Widens, Shares Drop 13%

by Zacks Equity Research

Brookdale Senior's (BKD) Q4 results were hit by inflationary challenges, an increase in facility operating lease expense and higher income tax provision. It expects adjusted EBITDA within $90-$95 million in first-quarter 2024.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.